As of 2025-05-19, the Intrinsic Value of Maxigen Biotech Inc (1783.TW) is 59.01 TWD. This 1783.TW valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 41.95 TWD, the upside of Maxigen Biotech Inc is 40.70%.
The range of the Intrinsic Value is 42.15 - 114.66 TWD
Based on its market price of 41.95 TWD and our intrinsic valuation, Maxigen Biotech Inc (1783.TW) is undervalued by 40.70%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 42.15 - 114.66 | 59.01 | 40.7% |
| DCF (Growth 10y) | 46.98 - 121.11 | 64.31 | 53.3% |
| DCF (EBITDA 5y) | 26.85 - 37.54 | 29.88 | -28.8% |
| DCF (EBITDA 10y) | 32.93 - 45.10 | 36.61 | -12.7% |
| Fair Value | 53.01 - 53.01 | 53.01 | 26.37% |
| P/E | 40.08 - 48.47 | 42.11 | 0.4% |
| EV/EBITDA | 21.53 - 41.77 | 28.44 | -32.2% |
| EPV | 29.42 - 35.46 | 32.44 | -22.7% |
| DDM - Stable | 19.01 - 68.57 | 43.79 | 4.4% |
| DDM - Multi | 25.27 - 68.15 | 36.55 | -12.9% |
| Market Cap (mil) | 3,762.08 |
| Beta | 0.53 |
| Outstanding shares (mil) | 89.68 |
| Enterprise Value (mil) | 3,123.02 |
| Market risk premium | 5.98% |
| Cost of Equity | 8.30% |
| Cost of Debt | 5.00% |
| WACC | 6.26% |